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Abstract 
Isochromosome i(22)(q10) is a rare but non-random 
karyotypic change in hematologic malignancies, 
often associated with complex karyotypes and with 
partial or complete loss of chromosomes 5 and/or 7. 
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Partial karyotypes with i(22)(q10) (A). Fluorescence in situ 
hybridization with LSI BCR/ABL dual color probe revealing 
extra copy of the BCR gene on 22q11 as a result of 
isochromosome formation (Abott Molecular/Vysis, US) (B). 
Clinics and pathology 
Disease 
Chronic and acute myeloid malignancies 
Phenotype/cell stem origin 
Chronic myeloid malignancies in 7 (4 males and 3 
females aged 59 to 73 years, median 68 years): 
refractory anemia with excess of blasts in 5 
(Musilova & Michalova 1988; Geddes et al., 1990; 
Padua et al., 1998; Martinez-Ramirez et al., 2004; 
Lessard et al., 2007), 1 myelodysplastic syndrome 
(Andersen et al., 2005) and 1 chronic myeloid 
leukemia (Werner et al., 1991).  
Acute myeloid leukemia  in 16 (10 males and 6 
females; median age 61 years; range 2-76 years): 5 
with M2 (Berger et al., 1987; Van Limbergen et al., 
2002; Rucker et al., 2006; Xu et al., 2008; ), 2 with 
M4 (Shurtleff et al., 1995; Johansson et al., 1997; 
Asou et al., 2009; ), 1 with M5 (Gervais et al., 2008), 
1 with M6 (Bitter et al., 1985) and 7 with unspecified 
AML (Michels et al., 1989; Pedersen & Jensen; 
GFCH 1996; Morrison et al., 2002; Lugthart et al., 
2010; Haferlach et al., 2012; Lavallee et al., 2015). 
Epidemiology 
23 patients (14 males, 9 females aged 2 to 76 years; 
median 63 years). 
Prognosis 
The presence of i(22)(q10) in association with 
chromosome 5 and/or chromosome 7 anomalies in 
complex karyotypes is indicator of poor prognosis, 
representing a therapeutic challenge. 
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Cytogenetics 
To exclude the possibility that der(22) chromosome 
contain two centromeres, use of centromere 22-
specific FISH probes is recommended. 
Cytogenetics morphological 
Sole anomaly in 1 patient, loss of 5 and/or 7 
chromosomal material seemed the most common 
event, and their losses in combination were observed 
in many cases: found with del(5q)/-5 in 4, with 
simultaneous del(5q)/del(7q) or del(7q)/-7 in 8 and 
with monosomy of both chromosomes in 2. Found 
as an additional anomaly to inv(16)(p13q22) in 2 and 
with miscellaneous or highly complex anomalies in 
the remaining patients. 




While trisomy 22 is a well know anomaly in myeloid 
leukemia, in particular, acute myelomonocytic 
leukemia with eosinophilia, i(22)(q10) is less 
common. The i(22q) formation leads to the gain of 
the entire long arm of chromosome 22 suggesting its 
possible role in oncogenesis. Gain of the whole long 
arm leads to overexpression of genes located on 22q 
due to a dosage effect. i(22)(q10) is mainly found as 
part of complex karyotypes, therefore may not be the 
primary disease determining aberration but rather a 
secondary event associated with disease evolution. 
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